Beta Drugs DuPont analysis

·UnclassifiedChart ›

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025


0.76×	0.76×	0.74×
0.95×	0.93×	0.92×
16.7%	15.2%	17.1%
0.83×	0.83×	0.83×
1.38×	2.03×	—
13.8%	18.1%	—
18.8%	18.8%	21.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BETA₹1,896.00

Beta Drugs Limited

· Unclassified

₹ CrorePeersTHEJO MACPOWERSAKARSERVOTECHMcap ₹1,922 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.74	0.76	0.76
Interest Burden (Pretax/EBIT) ×	0.92	0.93	0.95
EBIT Margin %	17.14	15.21	16.69
Asset Turnover ×	0.83	0.83	0.83
Financial Leverage (Assets/Equity) ×	—	2.03	1.38
ROE (5-step product, year-end total equity) %	—	18.12	13.78
ROE (owners' profit / average owners' equity) %	21.52	18.78	18.78

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.